Kenvue Inc.
KVUEKenvue owns everyday health brands that consumers repeatedly buy, creating reliable cash flow built on trust.
Because boring, essential products with 58 percent gross margins can be powerful long term compounding machines.
Business Model
Branded health products
Sells over the counter medicines and personal care products through retailers worldwide.
Economic Engine
High gross margins
A 58.1 percent gross margin shows strong pricing power from trusted brands.
Long-Term Lens
Brand durability
The key question is whether its brands stay trusted and relevant for the next 20 years.
On this page
Company Story
How do Kenvue Inc.'s business model and economics hold up on a closer read?
Start with the business itself, then go one layer deeper into the model, the economics, and the long-term case.
“A steady, brand driven cash machine with modest growth, durable margins, and long term resilience if management protects its moat.”
What does Kenvue Inc. actually do?
Kenvue sells everyday health and personal care products that people buy again and again.
- Pain relief medicines like Tylenol and Motrin
- Skin care products like Neutrogena and Aveeno
- Oral care products like Listerine
Why it matters
Everyday demand
People need pain relief, skin care, and oral hygiene in good times and bad, which makes demand relatively stable.
How does Kenvue Inc. make money?
Kenvue makes money by selling branded consumer health products to retailers at a healthy markup.
- Gross margin of 58.1 percent shows strong pricing power
- Operating margin of 17.9 percent after marketing and distribution
- Free cash flow is 1.17 times net income, showing strong cash conversion
Economic clue
Cash backed profits
When free cash flow exceeds net income, it suggests the accounting earnings are backed by real cash.
Why do long-term investors keep Kenvue Inc. on the radar?
Kenvue can matter because trusted health brands can generate steady cash for decades if managed well.
- Large global footprint across multiple categories
- High gross margins that leave room for marketing and innovation
- Consumer defensive sector that tends to hold up in downturns
Investor takeaway
Durability over speed
This is not a fast grower, with 5 year average revenue growth of just 0.1 percent, but durability can be powerful over 20 years.
Based on company financial statements.
Benchmark Comparison
How has Kenvue Inc. performed against common long-term benchmarks?
Once the business case is clear, compare the stock against broad market and alternative long-term baselines.
$793.36
-20.7% total return
$1,174
+17.4% total return
$1,765
+76.5% total return
$757.42
-24.3% total return
| Asset | Total Return | Dollar Value |
|---|---|---|
| KVUE | -20.7% | $793.36 |
| S&P 500 | +17.4% | $1,174 |
| Gold | +76.5% | $1,765 |
| Bitcoin | -24.3% | $757.42 |
From Mar 6, 2025 to Mar 6, 2026. Historical price data based on company financial statements and market indices. Each card uses the same starting amount so the comparison stays apples-to-apples.
Investor Fit
How a first-time investor could frame Kenvue Inc.
Before going deeper, decide what kind of business this is, what it tends to suit, and what deserves monitoring over time.
This Can Fit If You Want
- Exposure to everyday consumer health products
- Stable cash generation with 11.4 percent free cash flow margin
- A defensive business that may hold up in recessions
Be Careful If You Expect
- Rapid revenue growth, 5 year average growth is 0.1 percent
- Breakthrough innovation that reshapes the industry
- Aggressive share buybacks or large dividend payouts, currently zero
What To Watch Over Time
- Whether revenue returns to steady low single digit growth
- Sustainability of 58 percent gross margins amid private label competition
- How management deploys growing cash flow
Key Metrics
Which metrics matter most for Kenvue Inc. right now?
Three durable business metrics that matter more than day-to-day price moves.
0.1% average over 5 years
-8.5% average over 5 years
58.1% gross margin
| Metric | Value | Context |
|---|---|---|
| Revenue Growth | 0.1% average over 5 years | Shows whether the business has been expanding fast enough to create more long term value. |
| EPS Growth | -8.5% average over 5 years | Shows whether earnings per share are compounding for owners over time. |
| Margin Quality | 58.1% gross margin | Shows how much room the business has to fund growth, absorb shocks, and stay profitable. |
Based on company financial statements.
Fundamentals
What do Kenvue Inc.'s fundamentals say right now?
Core financial markers that explain how the business is performing beneath the stock price.
9.5% ROIC
58.1% gross margin
11.4% FCF margin
Stable to shrinking
| Metric | Value | Interpretation |
|---|---|---|
| Capital Efficiency | 9.5% ROIC | The business is currently showing poor capital efficiency. |
| Profitability | 58.1% gross margin | Healthy gross margins give the company room to invest, price competitively, and absorb shocks. |
| Cash Generation | 11.4% FCF margin | Free cash flow margin shows how much real cash the business keeps after funding operations and investment. |
| Ownership Trend | Stable to shrinking | The company is not currently diluting owners and may be buying back shares instead. |
Based on company financial statements.
Included In Funds
Which ETFs and funds currently hold Kenvue Inc.?
Kenvue Inc. currently appears in these ETF and fund proxies.
SPY
SPDR S&P 500 ETF Trust
IWB
iShares Russell 1000 ETF
Questions & Answers
What questions come up most often about Kenvue Inc.?
Company-specific questions readers often ask about Kenvue Inc..
Each entry answers a direct question about the business, the long-term thesis, or the risks that matter over time.
Kenvue sells over the counter medicines and personal care products under well known brands like Tylenol, Neutrogena, and Listerine.
Decision Framing
Secondary context after the long-term thesis
Shorter-horizon context and comparison tools, after the core long-term read.
Shorter-horizon price moves, two-sided debate, and comparison tools live here so the page stays anchored on business quality, durability, and BinaPrint fit first.
Investment Thesis
Bull vs Bear
Two-sided framing before any decision.
Current argument weight is balanced.
Bull case
What can work
Decades old brands like Tylenol and Neutrogena carry trust that is hard to replicate, especially in health related categories where consumers are cautious about switching.
Aging populations globally mean more demand for pain relief, skin care, and self care products over the next 20 years.
High 58.1 percent gross margins provide room to invest heavily in marketing and product improvements while still generating strong cash.
Strong cash conversion, with free cash flow exceeding net income, gives management flexibility to compound value through dividends or smart acquisitions.
Bear case
What can break
Private label and generic products could steadily erode pricing power, compressing the 58 percent gross margin over time.
Retailers have growing bargaining power and can push for lower prices or favor their own store brands on shelf space.
Litigation or regulatory action in health related products could lead to large fines or product withdrawals that damage brand trust.
If consumer preferences shift toward niche or digital first wellness brands, legacy brands could lose relevance with younger buyers.
Risk Radar
Key Risks
Where downside pressure can build.
Margin pressure: a 5 percentage point drop in gross margin from 58 percent to 53 percent would meaningfully reduce operating profit.
Low growth: with 5 year average revenue growth of 0.1 percent, prolonged stagnation could limit long term returns.
Brand concentration: several flagship brands likely account for a large share of profit, increasing exposure to product specific issues.
Sizing matters
Risks should be read as scenario inputs, not certainties. Position size and time horizon determine how much of this downside profile is acceptable.
Market Snapshot
Tactical context after the core long-term read.
- Price
- $18.39
- Daily move
- +0.77%
Peer Set
A compact peer list for side-by-side context.
Next Actions
Explore planning scenarios or keep browsing similar companies.